Amicus Therapeutics, Inc.
|Company Name||Amicus Therapeutics, Inc.|
The Firm is investigating potential claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (Nasdaq: FOLD) concerning the Company’s and its officers’ possible violations of federal securities laws in connection with the Company’s recently announced delay in submitting a New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”).
On October 2, 2015, the Company disclosed that the FDA had “requested further integration of existing clinical data across studies” in connection with Amicus’s migalastat monotherapy treatment for Fabry disease, and that, “Amicus does not anticipate being in a position to submit the NDA for migalastat monotherapy in the United States by the end of this year.” On this news, the Company’s stock fell $7.36, or over 53%, to close at $6.39 on October 2, 2015, thereby injuring Amicus investors. News of the delay in the FDA approval process comes shortly after the Company completed an offering of securities to the public.
If you purchased Amicus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to firstname.lastname@example.org.
Submit Your Information
If you suffered a loss on your Amicus Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.